(July 3, 2025) – Following their meeting June 25-26, the Centers for Disease Control's Advisory Committee on Immunization Practices issued a joint statement summarizing the committee's recommendations. The committee voted to approve the respiratory syncytial virus monoclonal antibody drug, clesrovimab, for infants younger than 8 months and to include the treatment in the Vaccines for Children program. The FDA approved clesrovimab, branded as Enflonsia, in early June. Additionally, the committee reaffirmed recommendations for annual influenza vaccination of all persons aged over six months who do not have contraindications. Further, the committee recommended that eligible individuals receive seasonal influenza vaccines only in single-dose formulations that are free of thimerosal as a preservative. See
ACIP's June 26 Joint Statement for detailed information.
--
Karen Braman